medigraphic.com

2010, Number 3

Next >>

Rev Mex Med Repro 2010; 2.3 (3)

Ovarian hyperstimulation syndrome

Gaona AR, Cejudo Hernández GL

Language: Spanish
References: 31
Page: 67-73
PDF size: 79.04 Kb.


ABSTRACT

Drugs prescribed to induce ovulation in women with difficulties to achieve a pregnancy provoke potentially severe complications and may cause ovarian hyperstimulation syndrome, which is characterized by an increased ovarian volume, extravascular volume accumulation and reduced intravascular volume, electrolytic disorders, renal failure and tromboembolic disorders, which may put patient’s life at risk. This paper includes epidemiology, classification, risk factors, treatment, prevention and prognosis of ovarian hyperestimulation syndrome.


REFERENCES

  1. Beerendonk CM, van Dop PA, Braat DDM, et al. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Clin Surv 1998;53:439-449.

  2. Buyalos RP, Lee CT. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Fertil Steril 1996;66(1):173-174.

  3. Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-896.

  4. Delvigne A, Demoulin A. The ovarian hyperstimulation syndrome in vitro fertilization: a Belgian multicentric study: clinical and biological features. Hum Reprod 1993;8:1353.

  5. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978;30:255.

  6. Papanikolaou EG, Tournaye H, Verpoest W, et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Human Reproduction 2005;20:636-641.

  7. Gaona AR, García LA. Inseminación artificial intrauterina e hiperestimulación ovárica controlada. Trabajo de tesis de postgrado. México: HGO Luis Castelazo Ayala, 1999.

  8. Hammerstein J. Dangers of overstimulation in use of clomiphene and gonadotrophins. Geburtshilfe Frauenheilkd 1967;27:1125-1151.

  9. Kistner RW. Induction of ovulation with clomiphene citrate (clomid). Obstetric Gynecol Surv 1965;20:873-900.

  10. Rabau E, David A, Serr DM, et al. Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am J Obstet Gynecol 1967;98:92-98.

  11. Golan A, Ron-El R, Herman A, et al. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 1989;44:430-440.

  12. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-261.

  13. Lyons D, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Human Reprod 1994;9:792-799.

  14. Navot D, Relou A, Birkenfeld A, et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988;159:210-215.

  15. Asch RH, Balmaceda HP, Weckstein JP, et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991;6:1395-1399.

  16. Enskog A, Henriksson M, Unander M, et al. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808-814.

  17. Balasch J, Fábregues F, Arroyo V, et al. Treatment of severe ovarian hyperstimulation syndrome by conservative medical approach. Acta Obstet Gynecol Scand 1996;75:662-667.

  18. Schenker JG. Clinical aspects of ovarian hyperstimulation syndrome. Eur J Obset Gynecol Reprod Biol 1999;85:13-20.

  19. Aboulghar M. Elevated levels of interleukin in patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1999;87:81

  20. Otani N, Minami S, Yamoto M. The vascular endothelial growth factor/fms like tyrosine-kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab 1999;84:3845-3851.

  21. Baumann P, Diedrich K. Thromboembolic complications associated whit reproductive endocrinologic procedures. Hemat Oncol Clin North Am 2000;14(2):431-443.

  22. Yoshii F. Multiple cerebral infarctions associated with ovarian hyperstimulation syndrome. Neurology 1999;53(1):225.

  23. Bellver J, Muñoz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 2003;18:2283-2288.

  24. Aboulghar M, et al. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. 2002;17:3027.

  25. Raziel A, Friedler S, Schachter M, et al. Transvaginal drainage of ascites as an alternative to abdominal paracentesis in patients with severe ovarian hyperstimulation syndrome, obesity and generalized edema. Fertil Steril 1999;69:780-783.

  26. Aboulghar MA. Autotransfusion of the ascitis fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1992;58:1056.

  27. Barron VJ, Pereyra QR, Esparza IJA y col. Tratamiento integral del síndrome de hiperestimulación ovárica severo mediante autotransfusión de ascitis e infusión intravenosa de albúmina. Ginecol Obstet Mex 1994;66:347-349.

  28. Waldestrom U. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by prolonged coasting of very hyperstimulated patients: a multicentre study. Hum Reprod 1999;14:2947.

  29. Cochrane, del 1985 a 2002. “Coasting” (inhibición de gonadotropinas) para la prevención del síndrome de hiperestimulación ovárica.

  30. Orvieto R. Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005;20:320-322.

  31. Alvarez C, Martí-Bonmartí L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. Obstet Gynecol Surv 2008;63:28.




2020     |     www.medigraphic.com